Bilthoven, Netherlands-based Avania announced on October 8 its acquisition of Anagram. Founded in 1998, Anagram is a clinical research organization (CRO) based in Barcelona, Spain which provides services in clinical development and post-authorization trials with drugs and medical devices.
Anagram delivers a full-service CRO model to its customers including diagnostic imaging core lab (centralized quality control and central assessment of images in clinical trials) services. The company is focused on cardiology, oncology and neurology therapeutic areas. It conducts studies in the United States, United Kingdom, Spain, Netherlands, France, Germany and more.
Avania is a CRO with specialized expertise in medical devices, novel technology and combination products. It advances products from feasibility through post-approval trials in analytics, clinical trials, consulting, regulatory and reimbursement.
The addition of Anagram enables Avania to increase its CRO business in Spain. The addition will support cross-sell opportunities by adding scale and will eliminate reliance on current outsourcing partners. Avania customers will benefit from an expanded geographic footprint and an enhanced roster of subject matter experts concentrated on areas of key therapeutic expertise. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition represents the 23rd CRO deal of 2024. There were 44 CRO transactions announced during 2023 and 41 announced during 2022.
